No connection

Search Results

QURE

BEARISH
$17.58 Live
uniQure N.V. · NASDAQ
Target $38.61 (+119.6%)
$8.73 52W Range $71.5
Overview AI Snowflake Price Valuation Profitability Growth Health Statements Peers Insiders SEC Filings

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 18, 2026
Market cap
$1.1B
P/E
N/A
ROE
-207.1%
Profit margin
N/A
Debt/Equity
2.7
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
85%
The deterministic health profile is critical, highlighted by a Piotroski F-Score of 1/9, indicating severe financial deterioration. While the company maintains a high current ratio (10.43) providing a short-term liquidity buffer, the operating margin of -900.93% and a Price/Sales ratio of 68.29 suggest an extreme valuation disconnect from fundamental performance. Bearish insider activity from the CEO and CFO, combined with a 0/100 technical trend, outweighs the optimistic analyst target prices. The company remains a high-risk speculative play dependent on future clinical success and additional capital raises.

Key Strengths

Strong short-term liquidity with a current ratio of 10.43
Positive analyst sentiment with a mean target price of $38.61
Recent improvement in EPS growth (YoY +67.4%)
Market capitalization above $1B providing some institutional visibility
Active clinical trial progression as evidenced by recent 8-K filings

Key Risks

Extreme operational inefficiency with an operating margin of -900.93%
Severe valuation premium with a Price/Sales ratio of 68.29
High debt-to-equity ratio of 2.70
Heavy insider selling, including the CEO and CFO
Explicit 10-K warning regarding the need for additional financing to sustain operations

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
20
Weak
Value
10
Future
45
Past
30
Health
15
Dividend
0
AI Verdict
High-Risk Speculative
Key drivers: Piotroski F-Score 1/9, Extreme P/S Ratio, Negative Operating Margins, Insider Selling
Confidence
90%
Value
10/100

Ref P/E, PEG, Graham Number

Positives
No standout positives identified.
Watchpoints
  • P/S ratio of 68.29 is unsustainable
  • P/B ratio of 5.51 is high for a non-profitable entity
  • No Graham Number available due to lack of earnings
Future
45/100

Ref Growth rates

Positives
  • Improving EPS growth
  • Bullish analyst price targets
Watchpoints
  • Low revenue growth (6.6%) relative to biotech peers
  • Dependence on FDA approvals
Past
30/100

Ref Historical trends

Positives
  • 1Y return of +35.2%
Watchpoints
  • 5Y change of -46.9%
  • Consistent history of earnings misses
Health
15/100

Ref Altman Z-Score, Piotroski F-Score

Positives
  • High current and quick ratios
Watchpoints
  • Piotroski F-Score of 1/9
  • ROE of -207.10%
  • Debt/Equity of 2.70
Dividend
0/100

Ref Yield, Payout

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 dividend strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$17.58
Analyst Target
$38.61
Upside/Downside
+119.6%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for QURE and closest competitors.

Updated 2026-04-17
QUR
uniQure N.V.
Primary
5Y
-46.9%
3Y
-9.0%
1Y
+35.2%
6M
-69.7%
1M
+19.4%
1W
+14.3%
IVA
Inventiva S.A.
Peer
5Y
-63.3%
3Y
+67.0%
1Y
+70.8%
6M
+15.6%
1M
-20.7%
1W
-3.8%
NEO
NeoGenomics, Inc.
Peer
5Y
-83.1%
3Y
-45.5%
1Y
-14.1%
6M
-11.0%
1M
+1.3%
1W
+3.6%
INN
InnovAge Holding Corp.
Peer
5Y
-65.5%
3Y
+9.5%
1Y
+197.1%
6M
+60.5%
1M
-4.5%
1W
+7.8%
GER
Geron Corporation
Peer
5Y
+23.9%
3Y
-12.9%
1Y
+26.6%
6M
+26.6%
1M
+8.0%
1W
+6.0%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
-6.45
PEG Ratio
N/A
P/B Ratio
5.51
P/S Ratio
68.29
EV/Revenue
62.95
EV/EBITDA
-6.17
Market Cap
$1.1B

Profitability

Profit margins and return metrics

Profit Margin N/A
Operating Margin -900.93%
Gross Margin N/A
ROE -207.1%
ROA -16.21%

Growth

Revenue and earnings growth rates

Revenue Growth +6.6%
Earnings Growth N/A
Q/Q Revenue Growth +6.65%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
2.7
High debt
Current Ratio
10.43
Strong
Quick Ratio
9.99
Excellent
Cash/Share
$9.96

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
92.2%
Op. Margin
-924.8%
Net Margin
-666.1%
Total Assets
$0.8B
Liabilities
$0.6B
Equity
$0.2B
Debt/Equity
3.15x
Operating CF
$-0.1B
CapEx
$-0.0B
Free Cash Flow
$-0.1B
FCF Yield
100%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-05-07
$N/A
2026-03-02
$-0.47
+39.2% surprise
2025-11-10
$-1.19
-59.8% surprise
2025-07-29
$-0.6
+21.1% surprise

Healthcare Sector Comparison

Comparing QURE against 421 companies in the Healthcare sector (25 bullish, 134 neutral, 262 bearish)
Return on Equity (ROE)
-207.1%
This Stock
vs
-100.15%
Sector Avg
+106.8% (Excellent)
Debt to Equity
2.7
This Stock
vs
3.22
Sector Avg
-16.1% (Lower)
Revenue Growth
6.6%
This Stock
vs
121.05%
Sector Avg
-94.5% (Slower)
Current Ratio
10.43
This Stock
vs
4.55
Sector Avg
+129.2% (Stronger)

Similar Companies

Peer comparison within the same industry

QURE uniQure N.V.
BEARISH
Mkt Cap
$1.1B
P/E
-
ROE
-207.1%
Price
$17.58
IVA Inventiva S.A.
NEUTRAL
Mkt Cap
$1.1B
P/E
-
ROE
-%
Price
$5.26
 Compare with QURE
NEO NeoGenomics, Inc.
NEUTRAL
Mkt Cap
$1.1B
P/E
-
ROE
-12.4%
Price
$8.35
 Compare with QURE
INNV InnovAge Holding Corp.
BEARISH
Mkt Cap
$1.1B
P/E
164.0
ROE
1.2%
Price
$8.2
 Compare with QURE
GERN Geron Corporation
NEUTRAL
Mkt Cap
$1.1B
P/E
-
ROE
-33.0%
Price
$1.76
 Compare with QURE

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

KAPUSTA MATTHEW C
Chief Executive Officer
Stock Award
2026-03-04
70,600 shares
KAPUSTA MATTHEW C
Chief Executive Officer
Sell
2026-03-04
14,581 shares · $132,104
KLEMT CHRISTIAN
Chief Financial Officer
Stock Award
2026-03-04
39,600 shares
KLEMT CHRISTIAN
Chief Financial Officer
Sell
2026-03-04
12,000 shares · $108,720
POTTS JEANNETTE
Officer
Stock Award
2026-03-04
35,400 shares
POTTS JEANNETTE
Officer
Sell
2026-03-04
3,412 shares · $30,913
ABI-SAAB WALID
Officer
Stock Award
2026-03-04
41,700 shares
ABI-SAAB WALID
Officer
Sell
2026-03-04
808 shares · $7,320
O'KEEFE KYLIE
Officer
Stock Award
2026-03-04
19,800 shares
KAPUSTA MATTHEW C
Officer and Director
Sell
2026-03-02
34,437 shares · $342,648
KLEMT CHRISTIAN
Chief Financial Officer
Sell
2026-03-02
12,532 shares · $124,693
POTTS JEANNETTE
Officer
Sell
2026-03-02
8,578 shares · $85,351
ABI-SAAB WALID
Officer
Sell
2026-03-02
1,660 shares · $16,517
KAPUSTA MATTHEW C
Chief Executive Officer
Sell
2026-02-25
12,378 shares · $295,339
KLEMT CHRISTIAN
Chief Financial Officer
Sell
2026-02-25
6,217 shares · $148,338
Insider transactions can signal confidence or concerns about company prospects

SEC Filings

Recent regulatory filings from the SEC EDGAR database

8-K
8-K
2026-03-02

uniQure N.V. filed a current report on March 2, 2026, likely announcing material clinical trial results or financial updates.

10-K
10-K
2026-03-02

QURE's annual filing emphasizes critical considerations regarding its financial position, liquidity, and overall capital requirements. Key investor risks include the company's potential need for additional financing to sustain its operations.

8-K
8-K
2026-01-13
8-K
8-K
2026-01-09

uniQure N.V. filed an 8-K on January 9, 2026, likely reporting a corporate update or clinical trial progress presented at a healthcare conference.

8-K
8-K
2025-12-04
10-Q
10-Q
2025-11-10

QURE submitted its quarterly 10-Q filing on November 10, 2025. While specific financial highlights were not provided in the excerpt, the company includes standard cautionary language and safe harbor protections regarding its forward-looking statements.

8-K
8-K
2025-11-10
8-K
8-K
2025-11-03

uniQure N.V. reported its third-quarter financial results for 2025.

8-K
FORM 8-K
2025-09-29
8-K
FORM 8-K
2025-09-24
8-K
8-K
2025-09-24
8-K
FORM 8-K
2025-07-29
8-K
8-K
2025-07-29
10-Q
10-Q
2025-07-29
8-K
8-K
2025-06-13
Data sourced from SEC EDGAR. AI summaries generated automatically.

Wall Street Analysts

Professional analyst ratings and price targets

Consensus
BUY
11 analysts
Barclays
2026-03-23
Maintains
Equal-Weight Equal-Weight
Mizuho
2026-03-11
up
Neutral Outperform
HC Wainwright & Co.
2026-03-10
reit
Buy Buy
Chardan Capital
2026-03-09
Maintains
Buy Buy
RBC Capital
2026-03-09
up
Sector Perform Outperform
Wells Fargo
2026-03-09
up
Equal-Weight Overweight
Goldman Sachs
2026-03-03
Maintains
Neutral Neutral
Wells Fargo
2026-03-03
down
Overweight Equal-Weight
Chardan Capital
2026-03-03
Maintains
Buy Buy
Mizuho
2026-03-03
down
Outperform Neutral

Past News Coverage

Recent headlines mentioning QURE from our newsroom.

Newest → oldest
Back to All Stocks
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Features Terminal AI Assistant Analysis Market News Pricing
Start Trading with AI Already have an account? Sign In
Home
Terminal
AI
Markets
Profile